MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1

被引:0
|
作者
Vincent Huin
Francis Vasseur
Susanna Schraen-Maschke
Claire-Marie Dhaenens
Patrick Devos
Kathy Dupont
Nicolas Sergeant
Luc Buée
Arnaud Lacour
Hélène Hofmann-Radvanyi
Bernard Sablonnière
机构
[1] INSERM UMR837,Department of Molecular Biology
[2] Alzheimer and Tauopathies,Department of Clinical Neurology and Center for Rare Neuromuscular Diseases
[3] University Lille-Nord de France,University Versailles
[4] USDL,Saint Quentin en Yvelines, AP
[5] IMPRT,HP, Biochemistry and Molecular Genetics Laboratory
[6] Jean-Pierre Aubert Research Center,undefined
[7] EA2694,undefined
[8] Lille University Medical Center,undefined
[9] Lille University Medical Center,undefined
[10] Lille University Medical Center,undefined
[11] Hôpital Ambroise Paré,undefined
来源
Journal of Neurology | 2013年 / 260卷
关键词
Myotonic dystrophy; Disease severity; gene variants;
D O I
暂无
中图分类号
学科分类号
摘要
Myotonic dystrophy type 1 (DM1) is a multisystemic autosomal dominant disorder characterized by a highly variable phenotype and caused by an unstable CTG repeat expansion in the 3′ untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. Longer CTG repeat expansions often correlate with an anticipated age at onset and CTG repeat number may account for 45–60 % of the variance in disease severity. In order to search for candidate genes that could act as modifiers of disease severity, we studied the association between Muscleblind-like protein-1 (MBNL1) gene polymorphisms and the DM1 phenotype. In a group of 301 patients diagnosed with DM1 based on clinical symptoms, diagnosis was confirmed by molecular analysis of the DMPK gene. Patients were divided into four subtypes. The first subtype corresponded to asymptomatic patients or those with a mild phenotype, the second included those with a classic phenotype, the third concerned childhood onset, and the fourth corresponded to the congenital form of DM1. Three SNPs located in the MBNL1 gene promoter, rs323622, rs17283597, and rs17433672, were studied. Case–control analysis revealed that allele frequencies for the latter two were significantly associated with DM1 (p = 0.037 and p = 0.020). Multivariate linear regression analysis using phenotype as the dependent variable demonstrated that the TT genotype of the third SNP, rs323622, was associated with a more severe phenotype (p = 0.0034) and accounted for 1.88 % of the variance in disease severity. We report the association of several genetic variants of the MBNL1 gene with DM1 or with the severity of the disease.
引用
收藏
页码:998 / 1003
页数:5
相关论文
共 50 条
  • [1] MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1
    Huin, Vincent
    Vasseur, Francis
    Schraen-Maschke, Susanna
    Dhaenens, Claire-Marie
    Devos, Patrick
    Dupont, Kathy
    Sergeant, Nicolas
    Buee, Luc
    Lacour, Arnaud
    Hofmann-Radvanyi, Helene
    Sablonniere, Bernard
    JOURNAL OF NEUROLOGY, 2013, 260 (04) : 998 - 1003
  • [2] Identification of variants in MBNL1 in patients with a myotonic dystrophy-like phenotype
    Mirjam Larsen
    Wolfram Kress
    Benedikt Schoser
    Ute Hehr
    Clemens R Müller
    Simone Rost
    European Journal of Human Genetics, 2016, 24 : 1467 - 1472
  • [3] Sequestration of MBNL1 in tissues of patients with myotonic dystrophy type 2
    Lukas, Z.
    Falk, M.
    Feit, J.
    Soucek, O.
    Falkova, I.
    Stefancikova, L.
    Janousova, E.
    Fajkusova, L.
    Zaoralkova, J.
    Hrabalkova, R.
    NEUROMUSCULAR DISORDERS, 2012, 22 (07) : 604 - 616
  • [4] Identification of variants in MBNL1 in patients with a myotonic dystrophy-like phenotype
    Larsen, Mirjam
    Kress, Wolfram
    Schoser, Benedikt
    Hehr, Ute
    Mueller, Clemens R.
    Rost, Simone
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2016, 24 (10) : 1467 - 1472
  • [5] A Novel CUGexp•MBNL1 Inhibitor with Therapeutic Potential for Myotonic Dystrophy Type 1
    Jahromi, Amin Haghighat
    Lien Nguyen
    Fu, Yuan
    Miller, Kali A.
    Baranger, Anne M.
    Zimmerman, Steven C.
    ACS CHEMICAL BIOLOGY, 2013, 8 (05) : 1037 - 1043
  • [6] Role of RNA and MBNL1 Nuclear Foci in Pathomolecular Mechanism in Myotonic Dystrophy Type 1 and Type 2
    Meola, Giovanni
    Renna, Valentina
    Bugiardini, Enrico
    Giagnacovo, Marzia
    Pellicciari, Carlo
    Malatesta, Manuela
    Cardani, Rosanna
    NEUROLOGY, 2012, 78
  • [7] CUG repeat RNA-dependent proteasomal degradation of MBNL1 in a cellular model of myotonic dystrophy type 1
    Aoki, Yoshitaka
    Yanaizu, Motoaki
    Ohki, Ai
    Nishimiya, Kai
    Kino, Yoshihiro
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 733
  • [8] Chemogenomic screening identifies small molecule up-regulators of MBNL1 for the treatment of type 1 myotonic dystrophy
    Jones, Lyn
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [9] RBFOX1 Cooperates with MBNL1 to Control Splicing in Muscle, Including Events Altered in Myotonic Dystrophy Type 1
    Klinck, Roscoe
    Fourrier, Angelique
    Thibault, Philippe
    Toutant, Johanne
    Durand, Mathieu
    Lapointe, Elvy
    Caillet-Boudin, Marie-Laure
    Sergeant, Nicolas
    Gourdon, Genevieve
    Meola, Giovanni
    Furling, Denis
    Puymirat, Jack
    Chabot, Benoit
    PLOS ONE, 2014, 9 (09):
  • [10] Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression
    Gonzalez-Martinez, Irene
    Cerro-Herreros, Estefania
    Moreno, Nerea
    Garcia-Rey, Andrea
    Espinosa-Espinosa, Jorge
    Carrascosa-Saez, Marc
    Piqueras-Losilla, Diego
    Arzumanov, Andrey
    Seoane-Miraz, David
    Jad, Yahya
    Raz, Richard
    Wood, Matthew J.
    Varela, Miguel A.
    Llamusi, Beatriz
    Artero, Ruben
    MOLECULAR THERAPY NUCLEIC ACIDS, 2023, 34